Xilio Therapeutics Announces 2024 Annual Meeting of Stockholders on June 13

TL;DR

<b>Xilio Therapeutics is holding its 2024 Annual Meeting of Stockholders on June 13, 2024, to elect directors and ratify auditors.</b>

AI Summary

Xilio Therapeutics, Inc. (XLO) filed a Proxy Statement (DEF 14A) with the SEC on April 25, 2024. Xilio Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 13, 2024. The meeting agenda includes the election of two Class III directors for three-year terms. Stockholders will vote on ratifying Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2024. The record date for stockholders entitled to vote is April 16, 2024. Proxy materials are being provided via internet access to reduce costs and environmental impact.

Why It Matters

For investors and stakeholders tracking Xilio Therapeutics, Inc., this filing contains several important signals. The election of directors is a standard governance procedure crucial for the company's strategic direction and oversight. Ratifying the independent auditor ensures continued financial transparency and compliance with regulatory standards.

Risk Assessment

Risk Level: low — Xilio Therapeutics, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational risks indicated.

Analyst Insight

Stockholders should review the director nominees and auditor ratification to make informed voting decisions at the upcoming annual meeting.

Key Numbers

• 2 — Directors to be elected (Election of two Class III directors)
• 3 — Director term length (Three-year term expiring at the 2027 annual meeting)
• 2024 — Fiscal year end (Fiscal year ending December 31, 2024)

Key Players & Entities

• Xilio Therapeutics, Inc. (company) — Registrant name
• June 13, 2024 (date) — Date of annual meeting
• Ernst & Young LLP (company) — Independent registered public accounting firm
• April 16, 2024 (date) — Record date for stockholders
• April 25, 2024 (date) — Date proxy materials are sent

FAQ

Industry Context

Xilio Therapeutics operates in the pharmaceutical preparations industry, focusing on developing novel immunotherapies.

Regulatory Implications

The filing is a standard DEF 14A proxy statement, adhering to SEC regulations for public company annual meetings.

What Investors Should Do

1. Review the biographies and qualifications of the nominated directors.
2. Evaluate the rationale for ratifying Ernst & Young LLP as the independent auditor.
3. Ensure voting rights are exercised by the record date of April 16, 2024.

Key Dates

• 2024-06-13: 2024 Annual Meeting of Stockholders — Key date for voting on directors and auditor ratification.
• 2024-04-16: Record Date — Determines which stockholders are eligible to vote.
• 2024-04-25: Mailing of Notice of Internet Availability of Proxy Materials — Initiates the proxy voting period.

Year-Over-Year Comparison

This is a DEF 14A filing for the 2024 annual meeting, following standard proxy statement procedures.

Filing Documents

• xlo-20240613xdef14a.htm (DEF 14A) — 760KB
• xlo-20240613xdef14a_a003.jpg (GRAPHIC) — 9KB
• xlo-20240613xdef14a_a004.jpg (GRAPHIC) — 1KB
• xlo-20240613xdef14a_bg001.jpg (GRAPHIC) — 118KB
• xlo-20240613xdef14a_bg002.jpg (GRAPHIC) — 102KB
• 0001558370-24-005762.txt (&nbsp;) — 1079KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 18 DIRECTOR COMPENSATION 27 REPORT OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS 29 PROPOSAL NO. 2—RATIFICATION OF THE SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 30 SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS 31 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 32 STOCK OWNERSHIP AND REPORTING 35 STOCKHOLDERS SHARING THE SAME ADDRESS 37 STOCKHOLDER PROPOSALS FOR OUR 2025 ANNUAL MEETING 37 OTHER MATTERS 37 Table of Contents 828 Winter Street, Suite 300 Waltham, Massachusetts 02451 (857) 524-2466 PROXY STATEMENT 2024 ANNUAL MEETING OF STOCKHOLDERS To Be Held on June 13, 2024 INFORMATION CONCERNING SOLICITATION AND VOTING This proxy statement and the enclosed proxy card are being furnished in connection with the solicitation of proxies by the board of directors of Xilio Therapeutics, Inc., or Xilio, for use at the annual meeting of stockholders, or annual meeting, to be held virtually on June 13, 2024 at 11:00 a.m., Eastern Daylight Time, and at any adjournment thereof. The annual meeting will be held exclusively online as a virtual meeting at www.virtualshareholdermeeting.com/XLO2024 . There will not be a physical meeting location, and stockholders will not be able to attend the annual meeting in person. Further information about how to attend the annual meeting online, vote your shares and submit questions during the meeting is included in this proxy statement. In this proxy statement, unless expressly stated or the context otherwise requires, references to "Xilio," "the company," "we," "us," "our" and similar terms refer to Xilio Therapeutics, Inc. References to our website are inactive textual references only, and the contents of our website are not incorporated by reference into this proxy statement. We are making this proxy statement, the related proxy card and our 2023 annual report to stockholders available to stockholders on or about April 25, 2

View Full Filing

View this DEF 14A filing on SEC EDGAR